Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SM08502 |
| Synonyms | |
| Therapy Description |
SM08502 is a small molecule inhibitor of Wnt signaling that inhibits CDC-like kinase (CLK), potentially resulting in decreased tumor cell proliferation (PMID: 31560935, PMID: 39258426). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SM08502 | SM-08502|SM 08502|Cirtuvivint | WNT Inhibitor 17 | SM08502 is a small molecule inhibitor of Wnt signaling that inhibits CDC-like kinase (CLK), potentially resulting in decreased tumor cell proliferation (PMID: 31560935, PMID: 39258426). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06484062 | Phase I | SM08502 Decitabine and Cedazuridine + SM08502 | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | Recruiting | USA | 0 |
| NCT03355066 | Phase I | SM08502 | A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT07032285 | Phase II | SM08502 | Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas (CIRTUSARC) | Recruiting | ESP | 0 |